Screener
Celldex Therapeutics CLDX Other Non-Current Assets
Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Property and equipment, net | 9,756 | 5,334 |
| Operating lease right-of-use assets, net | 5,038 | 2,437 |
| Intangible assets | 27,190 | 27,190 |
| Other assets | 15,434 | 13,358 |
| Total assets | $782,349 | $582,983 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $14,675 | $1,180 |
Item 1. Unaudited Financial Statements
FAQ
- What is Celldex Therapeutics's other non-current assets?
- Celldex Therapeutics (CLDX) reported other non-current assets of $15.43M in Q2 2026.
- How has Celldex Therapeutics's other non-current assets changed year-over-year?
- Celldex Therapeutics's other non-current assets increased by 66.0% year-over-year, from $9.3M to $15.43M.
- What is the long-term trend for Celldex Therapeutics's other non-current assets?
- Over 5 years (2020 to 2025), Celldex Therapeutics's other non-current assets has grown at a 218.1% compound annual growth rate (CAGR), from $41K to $13.36M.
- What does other non-current assets mean?
- Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.
Ask your AI about Celldex Therapeutics's other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude